title: Epoxygenase products of arachidonic acid are endogenous constituents of the hypothalamus involved in D2 receptor-mediated, dopamine-induced release of somatostatin.
abstract: The epoxyeicosatrienoic acids (EETs) were discovered as products of a cyclooxygenase/lipoxygenase-independent, cytochrome P-450 catalyzed metabolism of arachidonic acid (AA) termed the "epoxygenase" pathway. The rat hypothalamus is able to synthesize EETs from exogenous AA, and 5,6-EET has been found to release the neuropeptide somatostatin (SRIF) from hypothalamic nerve terminals of the median eminence (ME). In the present study, hypothalami from male rats were examined for the presence of endogenous EETs, using chemical, chromatographic, and mass spectral analysis procedures. The samples were initially separated in a C18 Sepralyte column, fractionated on TLC plates, and purified by reverse phase HPLC. Thereafter, they were esterified (pentafluorobenzyl esters) and subjected to negative ion chemical ionization/gas chromatography (GC)/mass spectral (MS) analysis. The GC retention time and the MS fragmentation patterns revealed the presence of a mixture of 8,9-, 11,12- and 14,15-EETs; instability of 5,6-EET during the isolation protocol precluded its identification. Total hypothalamic EET concentration was estimated to be 120 ng/g wet tissue. The 8,9-regiosomer released SRIF from ME nerve terminals with an ED50 of 5 x 10(-12) M; Dopamine (DA) and the D2 receptor agonist PPHT, but not the D1 receptor agonist SKF-38393, induced SRIF release from the ME. This effect was blocked by clotrimazole and ketoconazole, two inhibitors of microsomal cytochrome P-450 function and AA epoxygenase in particular. In contrast, the inhibitors failed to affect the increase in SRIF release induced by 8,9-EET. These results indicate that: 1) in addition to cyclooxygenase and lipoxygenase products, epoxygenase metabolites of AA are endogenous compounds of the hypothalamus, and 2) EETs may mediate the increase in SRIF release from hypothalamic neurons induced by the interaction of DA with D2 receptors.
authors.affiliation: Division of Neuroscience, Oregon Regional Primate Research Center, Beaverton 97006.
authors.forename: M P
authors.initials: MP
authors.lastname: Junier
authors.forename: F
authors.initials: F
authors.lastname: Dray
authors.forename: I
authors.initials: I
authors.lastname: Blair
authors.forename: J
authors.initials: J
authors.lastname: Capdevila
authors.forename: E
authors.initials: E
authors.lastname: Dishman
authors.forename: J R
authors.initials: JR
authors.lastname: Falck
authors.forename: S R
authors.initials: SR
authors.lastname: Ojeda
mesh_terms: D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism*; D002845:Chromatography; D004298:Dopamine / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D007031:Hypothalamus / Q000378:metabolism*; D008297:Male; D013058:Mass Spectrometry; D010105:Oxygenases / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000502:physiology*; D017448:Receptors, Dopamine D2; D013004:Somatostatin / Q000378:metabolism*
chemical_list: D001095:Arachidonic Acids; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D016718:Arachidonic Acid; D013004:Somatostatin; D010105:Oxygenases; D004298:Dopamine